Suchergebnisse - "van de Donk, Niels W C J"

PubPharm (215)

91

Sequencing multiple myeloma therapies with and after antibody therapies

enthalten in: Hematology. American Society of Hematology. Education Program | 2020

von van de Donk, N.

92

Should all newly diagnosed MM patients receive CD38 antibody-based treatment?

enthalten in: Hematology. American Society of Hematology. Education Program | 2020

von Korst, C. | van de Donk, N.

93

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial

enthalten in: Haematologica | 2020

von Zweegman, S. | Stege, C. | Haukas, E. | +23

94

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma

enthalten in: Oncotarget | 2020

von Verkleij, C. | Frerichs, K. | Broekmans, M. | +7

95

Immunotherapy in multiple myeloma : when, where, and for who?

enthalten in: Current opinion in oncology | 2020

von Verkleij, C. | Korst, C. | van de Donk, N.

96

Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies

enthalten in: Molecular cancer therapeutics | 2020

von Lu, H. | Molony, R. | Chen, D. | +24

97

Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma

enthalten in: HemaSphere | 2020

von Zajec, M. | Frerichs, K. | van Duijn, M. | +7

98

Management of patients with multiple myeloma in the era of COVID-19 pandemic : a consensus paper from the European Myeloma Network (EMN)

enthalten in: Leukemia | 2020

von Terpos, E. | Engelhardt, M. | Cook, G. | +15

99

Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities

enthalten in: Leukemia | 2020

von Stege, C. | van der Holt, B. | Dinmohamed, A. | +6

CommentOn: Leukemia. 2020 Jan;34(1):224-233. - PMID 31427722

100

Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma : a randomized, open-label, multicenter, phase 2 study (CENTAURUS)

enthalten in: Leukemia | 2020

von Landgren, C. | Chari, A. | Cohen, Y. | +18